Retatrutide Dosing: The Doses, Starting Dose and Escalation Used in the Trials

Retatrutide has no approved dose, because it has no approval. What exists are the doses Eli Lilly tested: in phase 3, everyone assigned to the drug started at 2 mg once a week and stepped up every four weeks to a fixed target of 4, 9 or 12 mg.^[9] The 12 mg dose produced the most weight loss in every trial that tested it. The final step from 9 to 12 mg added little, and in two trials it came with a higher dropout rate for adverse events.^[9][10] A “retatrutide dosing chart” sold alongside a vial is not one of these protocols.

There is no retatrutide dose to look up

An approved drug comes with a label, and the label sets the starting dose, each step up and the ceiling. Retatrutide has none of that. In August 2026 Lilly said no medicine containing retatrutide had been approved for human use by any regulator anywhere.^[13] Its stated plan is to file a Biologics License Application with FDA in Q1 2027.^[12] Until FDA reviews that application and approves a label, the only legitimate retatrutide doses are the ones written into a trial protocol and given to enrolled participants.

So a dosing question has to start from the trial record. It shows which doses were tested, how participants got there, and what each dose did. It does not show which dose a regulator will approve, and the approved schedule could differ from every arm below.

Every dose the trials tested

The two phase 2 trials were dose-finding studies. They tested a spread of maintenance doses, and they deliberately tested different starting doses to see whether a gentler start made the drug easier to tolerate.^[1][3] Phase 2 included 8 mg; phase 3 replaced it with 9 mg and dropped the lowest doses. The diabetes paper says its results informed the doses chosen for phase 3.^[3] The phase 3 design paper says the doses and escalation were selected from phase 1 and 2 safety and efficacy data and exposure modeling.^[8]

The phase 3 escalation schedule

Every phase 3 trial with results so far used the same ladder. Lilly’s announcements describe it the same way each time: retatrutide began at 2 mg once weekly and rose in steps every four weeks until it reached the assigned target.^[9][10][11] The step doses are company-reported; the published abstracts give only the targets.

The design paper for the TRIUMPH program fits that timing: each 80-week trial had a 16-week escalation period followed by 64 weeks on the maintenance dose.^[8] Participants and staff did not know which target a person had been assigned, and the escalation followed a fixed schedule set in advance.

Two details matter for anyone reading a chart online. First, 6 mg was a step on the way to 9 or 12 mg, never a dose anyone stayed on. Second, the protocol allowed a permanent step down, but only under defined conditions: stomach side effects or poor food intake that had not improved with other measures, including an earlier attempt to drop and re-escalate; a BMI that fell to 22 or below; or a participant who felt they had lost too much weight.^[8] The ladder was a research schedule with a study team watching it, not a self-titration plan.

The starting dose: 2 mg against 4 mg

The question of where to start was tested directly in phase 2. In the obesity trial, two of the arms reached 4 mg and two reached 8 mg, one of each starting at 2 mg and one starting at 4 mg. The paper concluded that gastrointestinal side effects rose with dose and were partially reduced by the lower starting dose.^[1] The trial’s posted results show the size of that difference.^[2]

Starting at 4 mg doubled the share of people with nausea on the way to 4 mg and more than tripled it on the way to 8 mg, where it reached 60%. The faster start bought slightly more weight loss at 48 weeks, about 1.5 to 2.2 percentage points. Each of these arms held only 33 to 35 people, and the comparison was not the trial’s main question, so the gaps are a direction, not a precise measure.

The diabetes trial pointed the same way. Nausea was reported by 2 of 23 people who reached 4 mg through a 2 mg step, against 6 of 24 who began at 4 mg, and by 7 of 26 on the slower route to 8 mg against 10 of 24 on the faster one.^[4] The 8 mg fast-escalation arm had the highest rate of gastrointestinal events in that trial, at 50%.^[3] Phase 3 then started everyone at 2 mg. That is the closest thing the record holds to a “retatrutide starting dose,” and it is a protocol choice, not a recommendation.

What each step up bought

The pattern repeats across all four trials. Going from 4 to 9 mg bought the larger gain: 6.1 percentage points in TRIUMPH-1 and 4.9 in TRIUMPH-2.^[5][6] Going from 9 to 12 mg bought less: 1.3 points in TRIUMPH-1, 2.0 in TRIUMPH-2, 1.4 in TRANSCEND-T2D-1 and 1.0 in TRIUMPH-3.^[7][10] Phase 2 showed the same flattening at the top, with 22.8% on the combined 8 mg arms and 24.2% on 12 mg at 48 weeks.^[1]

The 4 mg dose deserves attention for a different reason. It is reached after a single four-week step, and in TRIUMPH-1 it produced 17.6% weight loss over 80 weeks, against 3.9% on placebo.^[5] Lilly’s own announcement stressed that point.^[9] Whether the eventual label includes 4 mg is for the FDA review to settle.

People with type 2 diabetes lost less at every dose, as they do on every drug in this class. Those trials also measured blood sugar, which is covered in the TRANSCEND-T2D-1 write-up. For how the press-release figures and the journal figures for the same trial differ, see what the retatrutide evidence shows.

What each step up cost in tolerability

At 4 mg, discontinuation for side effects sat within about two points of placebo, and in TRIUMPH-1 slightly below it.^[9] At 12 mg it ran more than double placebo in TRIUMPH-1 and close to triple in TRIUMPH-3.^[9][10] TRIUMPH-2 is the exception that keeps this from being a clean line: more people stopped on 9 mg (12%) than on 12 mg (8%).^[6] The published paper reports the numbers without explaining the reversal, and a single trial cannot settle it.

Nausea followed the dose more cleanly. Lilly reported it in 28.6%, 38.4% and 42.4% of TRIUMPH-1 participants on 4, 9 and 12 mg, against 14.8% on placebo.^[9] The full breakdown of what people experienced, including the skin-sensation effect called dysesthesia, is on retatrutide side effects. For dosing, the upshot is that the last 3 mg bought one to two points of weight loss and, in two of the four trials, a clearly higher dropout rate.

Why a vial’s dosing chart is not a trial protocol

Sellers of research-labeled retatrutide often supply a dosing schedule, a chart or a calculator. FDA’s consumer page says companies have sold retatrutide and related drugs under research-only or not-for-human-use labels straight to consumers, with dosing instructions attached.^[14] A product that is not meant for people has no need for a dose.

“The standard, FDA-approved dosing schedule for Retatrutide is: Month 1: 0.25 mg per week…”^[15]

— Seller website, as quoted in FDA warning letter to GenLabMeds, September 2025

FDA found that seller’s claims false or misleading.^[15] Set the quote against the trial record and it fails twice. No FDA-approved schedule exists. And 0.25 mg matches none of the tested regimens: the lowest dose in any arm above is 0.5 mg, and phase 3 started at 2 mg. A chart can be copied from anywhere and still look clinical.

Even a chart that copied the TRIUMPH ladder exactly would not reproduce it. The ladder assumes the milligrams on the label are the milligrams in the vial. In the trials, the drug came from its manufacturer and was given under trial conditions. For a research-labeled vial, nobody independent has established what it contains. When researchers bought semaglutide vials from online sellers without a prescription, the vials claimed 99% purity and measured 7% to 14%, and the semaglutide they did contain ran 29% to 39% above the labeled amount.^[16] There is no approved retatrutide product to test a vial against, and a calculator that converts a labeled milligram figure into a dose inherits whatever error the label carries.

How to read the paperwork such sellers send is in how to read a peptide certificate of analysis. What the research-use label means for a buyer is in buying tirzepatide as a research chemical, and the FDA letters and online prices for retatrutide are in retatrutide price and release date. Retatrutide also cannot be compounded: FDA says federal law bars it.^[14]

If you want a weight-loss drug with a real dose today

The approved drugs in the same family come with exactly what retatrutide lacks: a label with a starting dose, a step-up schedule, a maximum, and a prescriber responsible for moving you along it. FDA’s concern with unapproved and compounded versions is partly about dosing itself; it has received adverse event reports, some involving hospitalization, that may be related to dosing errors with compounded semaglutide, and others that may be related to doses beyond the approved label.^[14] Tirzepatide, sold as Zepbound, is the nearest approved relative, a dual agonist made by the same company; its doses and prices are on our Zepbound page.

If retatrutide is approved, its label will settle the questions this page cannot: which doses, what starting point, how fast to climb. Until then, the trial ladder is a record of what was tested, not instructions.

Common questions